PAT101
Pipeline
- Program PAT101
- Active Substance Urate Oxidase-Albumin Conjugate
- Disease Refractory Tophaceous gout
- Development stage Non-Clinical
A novel bioconjugate drug candidate for refractory tophaceous gout,
aiming for the monthly administration
Comparison of MOA of gout drugs
-
Suppression of uric acid synthesis
Existing uric acid is not
subject to degradation -
Inhibition of uric acid reabsorption
Limitation in regulating
blood uric acid levels -
Uric acid degradation
Uric acid is eliminated through urine
PAT101 demonstrates an extended PK profile and reduced immunogenicity,
resulting in improved safety and efficacy compared to
commercially available drugs for treating chronic refractory gout.
